Skip to main content

Newsroom press releases

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)
Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)
Products Molecular
Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
Financial Data
Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)
Products Molecular
Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
Products Immunodiagnostic
Download

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)
Other
Download

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)
Other
Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
Financial Data
Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
Products Molecular
Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
Products Molecular
Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
Products Molecular
Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
Financial Data
Download

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)
Other
Download

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)
Other
Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
Financial Data
Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
Products Molecular
Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
Products Molecular
Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
Products Immunodiagnostic
Download

16/12/19 - 14:10

Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products Molecular
Download

06/12/19 - 18:12

Press Release (262.61 KB)
Other
Download

06/12/19 - 18:11

Press Release (262.7 KB)
Other
Download

06/12/19 - 18:08

Communication on total amount of voting rights (281.87 KB)
Other
Download

27/11/19 - 7:59

DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products Immunodiagnostic
Download

11/11/19 - 9:46

DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products Molecular
Download

06/11/19 - 13:00

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data
Download

30/10/19 - 9:55

DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products Immunodiagnostic
Download

22/10/19 - 14:10

DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products Immunodiagnostic
Download

07/10/19 - 10:20

Communication on total amount of voting rights (282.21 KB)
Other
Download

24/09/19 - 10:10

DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products Molecular
Download

31/07/19 - 13:00

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data
Download

10/06/19 - 18:23

DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data
Download

05/06/19 - 7:38

DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
Acquisition / Partnership Immunodiagnostic
Download

29/05/19 - 15:06

DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products Molecular
Download

09/05/19 - 13:14

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data
Download

06/05/19 - 15:19

DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products Immunodiagnostic
Download

30/04/19 - 12:28

Update Annual Calendar of Corporate Events 2019 (249.43 KB)
Other
Download

24/04/19 - 17:24

DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
Other
Download

12/04/19 - 8:59

Communication on total amount of voting rights (320.44 KB)
Other
Download

05/04/19 - 9:33

Communication on total amount of voting rights (342.47 KB)
Other
Download

03/04/19 - 20:18

Lists publication (79.68 KB)
Other
Download

03/04/19 - 10:32

DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products Immunodiagnostic
Download

14/03/19 - 14:16

Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data
Download

07/03/19 - 11:45

Communication on total amount of voting rights (350.08 KB)
Other
Download

06/03/19 - 8:45

A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
Other
Download

07/02/19 - 15:15

Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
Other
Download

31/01/19 - 22:30

DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products Immunodiagnostic
Download

03/01/19 - 13:30

DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products Molecular
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.